327 results about "Hirudin" patented technology

The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function preferably provided by heparin, antithrombin, hirudin, TFPI, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).

The invention provides a method for repeatedly extracting natural hirudin from live vampire leech. The method comprises the steps of: firstly extracting crude natural hirudin from the live vampire leech, then carrying out separation and purification to obtain natural hirudin, wherein the extraction of the crude natural hirudin comprises the steps of: firstly preparing specific induction liquid and then pouring into intestinal canal to obtain specific induction liquid-containing intestinal canal; then feeding the specific inducing liquid-containing intestinal canal to the vampire leech, and extracting the spit of the vampire leech or grinding the vampire leech into slurry, thereby obtaining the crude natural hirudin; and the crude natural hirudin is separated and purified to obtain natural hirudin powder according to a conventional biochemical separation method. The method is simple in process, and high in extraction rate, the death rate of the vampire leeches can be obviously reduced after the crude natural hirudin is extracted, and biological resource utilization rate can be effectively improved, so that the production cost can be obviously lowered; therefore, the method is a convenient approach for extracting the main effective active substance (such as natural hirudin) from the leech body.

The invention discloses a production method of natural hirudin. The production method is characterized by comprising the steps of extracting, acid depositing, heating, dehydrating and drying natural hirudin liquid, wherein the content of active ingredients of the obtained natural hirudin powder can be detected through Markwardt direct thrombin titration so that the quality is stable and the curative effect of the product is ensured. The method has the characteristics of simple process, high extraction ratio, low production cost, high product purity, long storage period and the like and can beused for providing safe and high-quality raw materials for foods, health-care foods, medicines or cosmetics.

The invention discloses a vacuum test tube which comprises a vacuum tube containing hirudin as anticoagulant therein. The hirudin can be in the form of freeze-dried powder or spray-dried powder or aqueous solution, or modified with polyethylene glycol or encapsulated in liposome. The content of the hirudin in the vacuum tube is 100-2000 ATU per milliliter of blood. The hirudin has an amino acid sequence (see sequence 1 in the sequence table). The vacuum test tube of the invention is used in clinical biochemistry, clinical immunology, clinical hemorheology, immune prototype analysis, RT-PCR detection and clinical hematological examinations (except cruor parameters) and realizes versatility of laboratory examinations.

The invention discloses an extract method of the effective constituent of the Natural hirudin. The method is that the blood-sucking leech is washed cleanly by water and is added with the ethanol water with content of 15 per cent to 25 per cent to soak for 30h to 50h, and then is filtered to gain the filter liquor and dregs of a decoction; the Poecilobdella manillensis waste residue is broken into pieces and is added with aqueous acetone solution with content of 15 per cent to 25 per cent to soak, and then is filtered to gain the filter liquor; after recovering ethanol and acetone from the two-time filter liquor in the vacuum, the filter liquor is combined and frozen and dried in the vacuum conventionally to gain the product. The invention is simple in process, low in cost, higher in yield, good in product quality and long in retention period. The ''three wastes'' are not discharged in the whole production process, and the product can work as the raw material in such three fields as medicine, hairdressing and health food.

Polymers having non-thrombogenic properties can be prepared by copolymerizing monomers of at least three classes selected from (a) monomers having sulphate groups, (b) monomers having sulphonate groups, (c) monomers having sulphamate groups, (d) monomers having polyoxyalkylene ether groups, and (e) monomers having zwitterionic groups. The polymers can additionally be provided with anti-thrombogenic properties by including an additional comonomer having a pendant heparin (or hirudin, warfarin or hyaluronic acid) group. The polymers can be used as coating materials for medical devices, such as tubing or connectors, in order to provide them with non-thrombogenic, and optionally anti-thrombogenic, properties.

The invention provides a compound medicinal formulation with bioactivity, which comprises Chinese medicinal herbs and right amount of medicinal or edible adjuvant to obtain pharmaceutically or food acceptable preparation, the herbs includes (by weight ratio) chloris virgata swartz 20-85%, notoginseng 5-30%, ginkgo leaves powder 0-60%, Gaultheria yunnanensis (Franch.) Rehd. 0-50%, safflower 0-35%, Ligusticum wallichii 0-30%, astragalus root 0-32%, borneol 0-5%, hirudin 0-10%, lumbrukinase 0-13%, ancrod 0-3%.

The present invention provides a new type balloon dilation catheter which includes ballon and medication material coated on stent. Said medication material comes from one or two and more than two mixtures of heparin sodium, fiber degrading enzyme, serine proteinase, batroxobin, aspirin, genistein, hirudin and its recombined product, colchicine, sirolimus, biolimus, zotarolimus, tracrolimus, pimecrolimus, simvastatin, atorvastatin, pravastatin, ciclosporin, Anti-CD34, dexamethasone, bleomycin, plicamycin, daunomycin, mitomycin C, actinomycin D, taxol, celastrol, methopterin, 5-fluorouracil, cytarabine and 6-purinethol. The balloon is made of macromolecule nylon material, and the stimulation to blood vessel is far lower than the stent with metal structure.

The invention discloses a method for extracting hirudin form leech saliva. The method includes the following steps of a), placing leeches in a container to allow the leeches to be hungered sufficiently, inputting inductive substances to the leeches to allow the same to absorb fully, adding vomitives to allow the leeches to spit the saliva in bodies, taking out blood-sucking leech living bodies to return to a rearing pond to feed continuously, and meanwhile, collecting hirudin crude product liquid in the container; b), freezing above hirudin crude products, adding into precooled cold acetone, stirring prior to placing in a refrigerator for setting overnight, sucking supernatant acetone the next day prior to centrifuging, adding a trichloroacetic acid solution, and centrifuging to remove residues to obtain concentrated liquid; c), eluting the above concentrated liquid with an anion exchange column chromatography method, and performing gel filtration chromatography to obtain finished products. The method has the advantages of reasonable process, convenience and practicability in operation, good quality stability of the finished hirudin products and high yield, one-time pillage on the leeches with a traditional method can be avoided, wild resources of the leeches are protected, and development of leech farming is driven.

The invention discloses a freeze dry injection of hirudin and its preparation process. It is characterized in that hirudin is extracted from fresh leech, pharmaceutic adjuvant can be added or not added after purification to prepare freeze dry injection formulation of hirudin, the character also lies in not adopting any organic solvent in the preparation method, but adopting purification methods of ultra filtration, ion exchange column chromatography and reverse osmosis condensation to get hirudin with comparative highly purity. The pharmacody experiment result indicates that the freeze dry injection has a favorable pharmacological action.

The invention discloses a vascular stent coating with a drug sustained-release function, which is prepared from the following raw materials: polycaprolactone, chitosan, collagen, medicine, nano magnesium, nano titanium dioxide, dendrobium polysaccharide, tea polyphenol, dopamine, gelatin, nano zirconia, hirudin, and ethanol. The invention also discloses a preparation method of the vascular stent coating with the drug sustained-release function. The binding strength of the vascular stent coating and a substrate is 4.8 to 5.9 MPa, the binding strength of the vascular stent coating and the stent substrate is high, the degradation time of the vascular stent coating is 68 to 86 days, the vascular stent coating can be completely degraded after 90 days, the large-area shedding and swelling phenomena do not occur in the degradation process, the stability and biocompatibility are good, no cell toxicity, coagulation and thrombosis are formed, and no inflammatory response is generated.

The invention discloses a large-scale production method for natural hirudin. The method comprises the following steps: placing a living hematophagous leech body which has thoroughly absorbed an induction liquid into a container and adding a certain amount of an emetic to allow the living hematophagous leech body to vomit saliva in its body, wherein the saliva is a crude natural hirudin product liquid, and the emetic is a zinc sulfate solution or a mixed liquor of zinc sulfate and ethanol; then taking out the living hematophagous leech body, flushing the living hematophagous leech body with clean water and continuing breeding the living hematophagous leech body for subsequent extraction; collecting the crude natural hirudin product liquid in the container; and adding a proper amount of a filler, carrying out mixing and then carrying out drying so as to obtain a finished powder product which is the natural hirudin product. According to the invention, a Markwardt thrombin direct titration method can be used to detect the content of active components in the natural hirudin product so as to guarantee stable quality and the curative effect of the product. The method has the characteristics of capacity of realizing large-scale production, simple process, a high recovery rate, low production cost and is capable of providing a safe and high-quality raw material for food, health food, medicines or cosmetics.

The present invention relates to a blood vessel medicine scaffold, including blood vessel scaffold, medicine and carrier, in which the medicine is coated on the surface of said blood vessel scaffold by means of carrier. The described medicine is rolimus medicine or mixture of rolimus medicine and taxol and/or hirudin, and said rolimus medicine is one of sirolimus, tacrolimus and eotarolimus or mixture of more than two kinds of them.

The invention belongs to the field of cosmetics and particular relates to hirudin skin-whitening moisture-keeping conditioning cream and a production process thereof. The conditioning cream is prepared by oil phase raw materials such as squalane, polyoxyethylene stearyl alcohol ether, jojoba oil, white oil, ferulic acid derivative, cetostearyl alcohol and evening primrose oil, and water phase raw materials such as hirudin, oat polypeptide, a saffron crocus extracting solution, collagen polypeptide, caffeine derivative and an epidermal growth factor. The production process comprises the steps of heating, sterilization, stirring, dissolving, emulsifying, homogenizing, cooling, discharging, sampling, detection, filling, and packaging to obtain the conditioning cream. The conditioning cream can permeate into a corium layer of skin autonomously and directly, can be easily absorbed by the skin, can solve the problems such as the lusterless skin caused by pore blockage, has a better skin-whitening, moisture-keeping and skin-softening effect, and can promote regeneration of the skin and improve the skin quality; as multiple skin-whitening, moisture-keeping and skin-tone-improving raw materials are added, the conditioning cream can improve blood circulation and the skin elasticity, and has very good skin-whitening, moisture-keeping and skin-softening effects; and the production process is simple and easy to operate.

Disclosed is a natural hirudin ointment, wherein the formula contains natural hirudin and conventional ointment matrix, and each 100g of the ointment contains natural hirudin 100-200000 international units. The ointment can be used for treating thrombotic phlebitis, burns, skin cracks, skin ulcer, chilblain, acne, acne and hemorrhoid.

The invention provides a preparation method of a silk fibroin anticoagulant material. The preparation method comprises the following steps: (S1) mixing a silk fibroin solution and polyethylene glycol diamine with a cross-linking agent for carrying out a reaction, then carrying out dialysis, and drying to obtain a polyethylene glycol diamine cationized silk fibroin material; (S2) dipping the polyethylene glycol diamine cationized silk fibroin material into a hirudin solution to obtain the silk fibroin anticoagulant material. Compared with the prior art, the preparation method provided by the invention protects a functional group at a thrombin bonding region from being affected by the reaction so as to prevent the influence on a structural domain bonded with the thrombin, and also can enable hirudin to be bonded onto the polyethylene glycol diamine cationized silk fibroin by means of an ionic bond with a stronger bonding force, thus achieving the effect of stably giving play to anticoagulation; therefore, the obtained silk fibroin anticoagulant material has an obvious function of inhibiting the activity of the thrombin, and is especially applied to prevention of the neointimal hyperplasia and postoperative thrombus formation of artificial blood vessels.

The invention discloses a hirudin vacuum blood collection tube. A hirudin coating is coated on the inner wall of a tube body, wherein the hirudin content is 0.005 to 1 milligram per milliliter of blood. The tube has the advantages that: 1, the tube can replace an anticoagulant commonly used in clinic, save the trouble of ordering in blood collection, apply to various kinds of examination, facilitate the operation of doctors and relive pains in patients; 2, as the hirudin used in the tube is a biological reagent, so the examination result is reversible and once the clinic examination fails, examination can be performed again directly without drawing block again for test; 3, the anticoagulation time is as long as more than 7 days; 4, the interference with blood is zero so as not to cause hemolytic reaction; 5, impurities and heavy metals are avoided; 6, more than 300 examination items can be performed; and 7, the biological reagent is environmental-pollution free.

The invention provides a new method of fusion expressing a small molecular protein (polypeptide). The new method is characterized by comprising the following steps: using hirudin as a fusion partner (label), splicing the protein (polypeptide) with a small molecular mesh to the downstream of the hirudin as the fusion partner to carry out fusion expression, designing a connecting peptide (which contains protease or a chemical cutting site or intein as a self-cuttable protein intron) between the fusion partner and a target protein (polypeptide), and releasing the target protein (polypeptide) by restriction enzyme digestion or chemical cutting or induced self cutting after fusion protein expression. The new method has the advantages that (1) as the hirudin as the fusion partner (label) is smaller (with the molecular weight of 7Kd), the rate of the protein (polypeptide) with the small molecular mesh accounting for a fusion protein can be effectively increased, and the yield of the target small molecular protein (polypeptide) is finally increased; (2) the hirudin still has the anticoagulant activity after being fused as the fusion partner (label), and the expression and the purification of the fusion protein can be conveniently detected and traced in real time.

The invention discloses a fusing protein with plasminokin and anticoagulant function and DNA sequence to code the fusing protein, carrier with the DNA sequence and making method of fusing protein, which provides the application of fusing protein to prepare functional drug with peptide segment of continuous amino acid sequence as connecting structure, wherein the fusing protein connects 10-12 amino acids in the 55-66th amino acids sequence at IIIC end of hirudin with r-PA as t-PA bobbing mutant.

The invention relates to a hirudin production process that a Hirudinaria manillensis refrigerated fresh body is taken as raw material, which belongs to the pharmaceutical field of the traditional Chinese medicine, and relates to the active constituent extraction of animals. The invention aims at solving the problem that the traditional hirudin extraction process is difficult to be applied to the industrialized production. The process adopts the method that the hirudin is extracted from the whole Hirudinaria manillensis, thus the industrialized production can be operated. The Hirudinaria manillensis is rectified, and the pulp is distilled for three times with normal saline, and filtered. The filtrate is boiled and filtered, and protein is removed from the filtrate. The filtrate is collected, and after freezing, concentration and alcoholization, and the hirudin crude product is obtained. The hirudin crude product is washed with the normal saline, and then washing solution is concentrated, and finally the product is obtained through freezing and drying. The production process method of the hirudin is simple, and the quality of the end product is qualified. The pharmacology experiment result indicates that the hirudin extracted by utilizing the process has good pharmacological action.

The invention relates to a method for extracting high-anticoagulation-activity hirudin from natural leeches, which comprises the steps that two kinds or a plurality of kinds of substances in sodium chloride, acetyl cysteine hydrochloride monohydrate, lysine, neutral protease and papain are combined and dissolved in deionized water to be prepared into stimulation liquid; the weight percentage concentration of each substance in the stimulation liquid is 0.01 to 5%, wherein the enzyme concentration is 100U to 300U/ml; the living leeches are weighed and placed into a container; the stimulation liquid is added according to the weight and volume ratio of the leeches to the stimulation liquid of 1 to (1-5); the leeches secrete exudate after the stimulation is carried out for 3 hours; the exudateis separated to obtain the hirudin crude product through 16000 to 20000r/min centrifugation; the hirudin crude product is micro-filtered through a stainless steel membrane with the thickness of 0.2 micrometer; the micro-filtration is carried out through an organic membrane with the molecular weight of 10000 to 3000 Dalton; the reverse osmosis, the nano-filtration and the concentration are carriedout; starch for drugs is added according to the weight and volume ratio of the solid to the liquid of 1 to (6-10) to allocate the mixture; and the spray drying is carried out to obtain the leech finished product. Finally, the extraction yield of the hirudin is above 30%, and the activity unit of the product is stabilized between 600AT-U/g to 1000AT-U/g.

The invention relates to a method for extracting hirudin by stimulating a living leech with electricity. By utilizing the simulating effect of current on organism glands, a way for simulating a living leech to extract high-purity hirudin at mass by direct weak current is directly used, and the living character of the leech is maintained, therefore, the production process of hirudin is simplified,the product purity is improved, the wild leech resources are recycled, the production cost is reduced and the problem of seasonal disorder of production is solved. The hirudin extracted by using the method is subjected to nanofiltration water removal and decompression spray drying to be made into powdery hirudin with the antithrombin activity of 800AT-U/g and liquid hirudin with the antithrombin activity of 1,000AT-U/g when protective agents are added in the liquid hirudin.